Cannvalate will begin selling products from Canadian manufacturer Avicanna (TSX:AVCN,OTCQX:AVCNF) thanks to a new supply agreement.

As part of the initial deal, Melbourne-based Cannvalate will obtain the right to sell the Rho Phyto line of products from Avicanna in Australia as the exclusive distributor.


The Canadian firm will also provide white-label products to Cannvalate alongside its branded items. The Rho Phyto products for the Australian market will be manufactured in Colombia through Avicanna’s subsidiary operations in the nation.

Aras Azadian, CEO of Avicanna, told investors that the Canadian firm underwent significant due diligence before stepping into the emerging Australian market. The executive said this agreement was designed for its medical cannabis product offerings.

The current line of Rho Phyto offerings from Avicanna includes a sublingual spray, oil drops, soft gel capsules and a topical cream and gel.

Sud Agarwal, CEO of Cannvalate, added that the firm will help Avicanna satisfy testing standards from Australia’s Office of Drug Control (ODC). “We have been particularly impressed by their attention to quality processes and firm stance on providing validated clinical research,” Agarwal said.

Cannvalate is a business-to-business services company for the medical marijuana industry.

Avicanna joins a running list of Canadian names pursuing active operations in Australia through partnerships or a direct presence. One of the most recent participants in the space, MPX International (CSE:MPXI,OTC Pink:MPXOF) announced in early February that it had obtained a medicinal cannabis licence from the ODC.

Shares of Avicanna opened at C$1.87 on Monday (February 24) in the Canadian markets. However, the company quickly dropped in value during the early portion of the trading session.

In a note to investors issued in January, Cameron Bell, an analyst with boutique bank Canaccord Genuity Australia, reassured readers that the market in the country was looking better after a sluggish 2019. The bank’s own index for Australian names had seen significant recent growth at the time thanks to easing concerns from offshore investors.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less